Innoviva Inc

Compare

318 Followers

INVA Stock Chart & Stats

$17.72

-$0.05(-0.29%)

At close: Jan 08 4:00 PM EST

$17.72

-$0.05(-0.29%)

Day’s Range― - ―

52-Week Range$16.52 - $22.00

Previous CloseN/A

Volume64.08K

Average Volume (3M)780.94K

Market Cap

$1.12B

Enterprise Value$1.72B

Total Cash (Recent Filing)$497.73M

Total Debt (Recent Filing)$450.90M

Price to Earnings (P/E)53.4

Beta0.34

Next Earnings

Oct 29, 2025

EPS Estimate

0.46

Last Dividend Ex-Date

Sep 08, 2015

Dividend YieldN/A

Share Statistics

EPS (TTM)0.77

Shares Outstanding63,021,015

10 Day Avg. Volume821,726

30 Day Avg. Volume780,936

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)1.57

Price to Sales (P/S)3.03

P/FCF Ratio5.78

Enterprise Value/Market Cap1.54

Enterprise Value/Revenue4.64

Enterprise Value/Gross Profit5.25

Enterprise Value/Ebitda15.39

Forecast

1Y Price Target

$38.00

Price Target Upside114.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial PerformanceInnoviva's financial results demonstrate strong underlying operational performance, with multiple revenue streams exceeding expectations.

Stock PerformanceStrong stock outperformance since 2021, with an increase of 80% compared to the XBI.

Strategic GrowthThe company's strategy centered on deploying cash flows from royalty revenues to build a commercial critical care and infectious disease platform has shown impressive growth.

Bears Say

Innoviva News

Innoviva initiated with a Sell at Goldman Sachs

Goldman Sachs initiated coverage of Innoviva (INVA) with a Sell rating and $17 price target The stock’s recent...

29d ago

INVA

Innoviva (INVA) Q3 Earnings Cheat Sheet

Innoviva (INVA) is scheduled to report 3rd quarter earnings on 10/29/2025. Regarding Q3 estimates, Wall Street analysts expect...

2d ago

INVA

Innoviva’s Future Challenges: Sell Rating Amid Patent Cliff and Revenue Pressures

Innoviva (INVA) has received a new Sell rating, initiated by Goldman Sachs analyst, Asad Haider. Asad Haider has...

27d ago

INVA

Arm initiated, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

ARM

Innoviva initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Innoviva (INVA) with an Outperform rating and $35 price target Innoviva is a holding...

3M ago

INVA

Innoviva price target raised to $45 from $40 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva (INVA) to $45 from $40 and...

3M ago

INVA

Innoviva Reports Strong Q2 2025 Financial Results

Innoviva ( ($INVA) ) has released its Q2 earnings. Here is a breakdown of the information Innoviva presented...

3M ago

INVA

Innoviva reports Q2 EPS 77c vs. (55c) last year

Reports Q2 revenue $100.3M vs. $99.9M last year. “Innoviva (INVA) continued to deliver impressive financial and operational results...

3M ago

INVA

INVA Upcoming Earnings Report: What to Expect?

Innoviva (INVA) is scheduled to report 2nd quarter earnings on 07/30/2025. Regarding Q2 estimates, Wall Street analysts expect...

3M ago

INVA

Innoviva initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Innoviva (INVA) with a Buy rating and $40 price target The firm says...

4M ago

INVA

Innoviva initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Innoviva (INVA) with an Overweight rating and $26 price target Published first on...

4M ago

INVA

Innoviva announces zoliflodacin NDA granted Priority Review by FDA

Innoviva (INVA) announced that the FDA has granted Priority Review for the New Drug Application for zoliflodacin, an...

5M ago

INVA

Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin

Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, in collaboration with the Global Antibiotic Research & Development Partnership,...

5M ago

INVA

Innoviva Elects Board Members and Approves Compensation

Innoviva ( ($INVA) ) just unveiled an update. At the Annual Meeting of Stockholders on May 19, 2025,...

5M ago

INVA

INVA FAQ

What was Innoviva Inc’s price range in the past 12 months?

Innoviva Inc lowest stock price was $16.52 and its highest was $22.00 in the past 12 months.

What is Innoviva Inc’s market cap?

Innoviva Inc’s market cap is $1.12B.

When is Innoviva Inc’s upcoming earnings report date?

Innoviva Inc’s upcoming earnings report date is Oct 29, 2025 which is today.

How were Innoviva Inc’s earnings last quarter?

Innoviva Inc released its earnings results on Aug 06, 2025. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.271.

Is Innoviva Inc overvalued?

According to Wall Street analysts Innoviva Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innoviva Inc pay dividends?

Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here

What is Innoviva Inc’s EPS estimate?

Innoviva Inc’s EPS estimate is 0.46.

How many shares outstanding does Innoviva Inc have?

Innoviva Inc has 63,021,015 shares outstanding.

What happened to Innoviva Inc’s price movement after its last earnings report?

Innoviva Inc reported an EPS of $0.77 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went up 1.151%.

Which hedge fund is a major shareholder of Innoviva Inc?

Currently, no hedge funds are holding shares in INVA

Innoviva Stock Smart Score

Neutral

Fundamentals

Return on Equity

5.60%

Trailing 12-Months

Asset Growth

8.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva (INVA) Earnings & Revenues

Historic Earnings Reports

INVA Stock 12 Month Forecast

Average Price Target

$38.00

▲(114.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","35":"$35","56":"$56","24.5":"$24.5","45.5":"$45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,24.5,35,45.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.88,23.504615384615384,26.12923076923077,28.753846153846155,31.378461538461536,34.003076923076925,36.62769230769231,39.252307692307696,41.87692307692308,44.50153846153846,47.12615384615385,49.75076923076924,52.37538461538462,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.88,22.196923076923078,23.513846153846153,24.83076923076923,26.147692307692306,27.464615384615385,28.78153846153846,30.09846153846154,31.415384615384617,32.73230769230769,34.04923076923077,35.36615384615385,36.683076923076925,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.88,20.58153846153846,20.283076923076923,19.984615384615385,19.686153846153847,19.38769230769231,19.089230769230767,18.79076923076923,18.49230769230769,18.193846153846152,17.895384615384614,17.596923076923076,17.298461538461538,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.12,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.35,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >